Whalesbook
SMS Pharmaceuticals has confirmed the complete utilization of the Rs. 114.30 crore raised from its preferential issue of convertible warrants. The company announced this in its monitoring agency report for the quarter ended March 31, 2026, submitted on May 15, 2026.
The report confirms that the entire amount raised has been deployed as planned. It details a minor reallocation of Rs. 0.54 crore that occurred between capital expenditure and general corporate purposes. This reallocation was well within the 10% shareholder-approved limit and was considered non-material. Crucially, the company stated that no delays were reported in the implementation of projects for which the funds were raised.
This preferential issue of convertible warrants, totaling Rs. 114.30 crore, was completed in March 2024. The funds were originally intended to support the company's working capital requirements and general corporate purposes.
The confirmation provides investors with assurance that the capital raised is being used as intended, reinforcing confidence in the company's stated objectives for the fundraising. With the funds fully deployed and projects progressing, SMS Pharmaceuticals can now focus on operationalizing these initiatives.
While the recent reallocation was minor and within approved limits, investors will be watchful for future fund reallocations. Any deviations exceeding the 10% shareholder-approved threshold could become a point of concern. Continued compliance with these limits will be key.
SMS Pharmaceuticals operates in the API and bulk drug manufacturing sector, alongside peers like Laurus Labs and Divi's Laboratories. While these peers often engage in more complex contract manufacturing, SMS Pharma's focus on core APIs supports its operational stability.
Key figures from the report include:
- Funds raised via preferential issue: Rs. 114.30 crore (March 2024)
- Monitored period: Until March 31, 2026
- Minor fund reallocation: Rs. 0.54 crore (Between March 2024 and March 31, 2026)
Looking ahead, investors will monitor future quarterly financial results for the impact of the deployed funds on revenue and profitability. Further announcements regarding project operationalization and management's commentary on capital allocation strategies will also be important.